Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Citi reiterates 'neutral' on Standard Chartered, welcomes investor update

(Sharecast News) - Citi reiterated its 'neutral' rating on Standard Chartered on Wednesday after the company's investor update a day earlier. In an update on Tuesday, StanChart announced plans to cut nearly 8,000 jobs and set higher medium-term profitability targets.

"We welcomed the investor update which clearly outlined the differentiating factors in the StanChart business model and where incremental investment is envisaged to position the bank for the future and drive structural top-line growth," Citi said.

"Trading on 1.1x P/TB for a more than 15% target return on tangible equity in 2028 and 5-7% target revenue compound annual growth rate, the stock appears inexpensive."

That said, Citi expects the initial debates will focus on the 2027-28 cost trajectory and capital allocation priorities, with the targets implying a step-up in cost growth and potentially lower buybacks than consensus assumes. This may limit consensus earnings per share upgrades and hold the shares back near-term, it said.

Share this article

Related Sharecast Articles

Berenberg downgrades Anglo American to 'hold'
(Sharecast News) - Berenberg downgraded Anglo American on Thursday to 'hold' from 'buy' as it took a look at metals and mining stocks, saying it was taking a "breather" following a strong share price performance.
FCA to take no action as it closes Drax probe
(Sharecast News) - Drax said on Thursday that the Financial Conduct Authority had closed its investigation into the company with no action to be taken.
Syncona reports broadly stable net asset value
(Sharecast News) - Syncona reported broadly stable net asset value for the year ended 31 March on Thursday, as gains at Beacon Therapeutics offset weakness elsewhere in its life sciences portfolio, while the healthcare investor reiterated plans to return at least £250m to shareholders.
Informa reaffirms outlook on strong start to the year
(Sharecast News) - Shares in Informa ticked higher on Thursday, after the media blue chip reaffirmed full-year guidance.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.